Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

HoxBlinc LncRNA Reprograms CTCF Independent TADs to Drive Leukemic Transcription and HSC Dysregulation in NUP98 Fusion Transformed Leukemia

Karina Hamamoto, Ganqian Zhu, Julia Lesperance, Huacheng Luo, Ying D Li, Nupur Nigam, Arati Sharma, Feng-Chun Yang, David F. Claxton, Yi Qiu, Peter D. Aplan, Mingjiang Xu, Suming Huang

Blood (2024) 144 (Supplement 1): 4108.

https://doi.org/10.1182/blood-2024-199171

Published: 2024

Journal Articles

Risk Factors for CMV Infection, Including HLA Disparity and Ptcy Transplant in the Era of Letermovir Prophylaxis

Blood (2023) 142 (Supplement 1): 4914.

https://doi.org/10.1182/blood-2023-187917

Published: 2023

Journal Articles

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial

Blood (2023) 142 (Supplement 1): 594.

https://doi.org/10.1182/blood-2023-189734

Published: 2023

Journal Articles

The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma

Jeffrey J. Pu, Kristin Berger, Chunlei Zheng, Nhan V Do, David F. Claxton, W Christopher Ehmann, Joseph J. Drabick, Thomas P. Loughran, Jr., Elliot Epner

Blood (2023) 142 (Supplement 1): 6152.

https://doi.org/10.1182/blood-2023-185797

Published: 2023

Journal Articles

Real World Outcomes of Chronic Myeloid Leukemia in Era of Tyrosine Kinase Inhibitors a Single Center Experience

Seema G Naik, Kevin L Rakszawski, Elizabeth Federici, David F. Claxton, Witold B. Rybka

Blood (2022) 140 (Supplement 1): 12225.

https://doi.org/10.1182/blood-2022-171007

Published: 2022

Journal Articles

Viridans Group Streptococcal Bacteremia after Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide

Blood (2022) 140 (Supplement 1): 7589–7590.

https://doi.org/10.1182/blood-2022-167227

Published: 2022

Journal Articles

Engraftment Kinetics and Recipient Chimerism Increase to Predict Leukemia Relapse By Ptcy and Non-Ptcy Transplant

Ruoheng Zhang, Kevin L Rakszawski, Myles Nickolich, W. Christopher Ehmann, Baldeep Wirk, Seema G Naik, Witold B. Rybka, Hong Zheng, Joseph Mierski, Brooke Silar, Gina Mackey, Jason Liao, Shouhao Zhou, Robert Greiner, Valerie Brown, David F. Claxton, Shin Mineishi, Hiroko Shike, Kentaro Minagawa

Blood (2021) 138 (Supplement 1): 1792.

https://doi.org/10.1182/blood-2021-148872

Published: 2021

Journal Articles

Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

Neil Palmisiano, Ju-Whei Lee, David F. Claxton, Elisabeth Paietta, Hassan B. Alkhateeb, Jae H Park, Nikolai Podoltsev, Ehab L. Atallah, Dale G Schaar, Shira Dinner, Jonathan Webster, Selina M. Luger, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2021-153621

Published: 2021

Journal Articles

DJ4 Targets Rho-associated Protein Kinase Pathway and Attenuates Disease Progression in Pre-clinical Murine Models of Acute Myeloid Leukemia

Melanie Ehudin, Upendarrao Golla, Charyguly Annageldiyev, Zheng Zeng, Diwakar Bastihalli Tukaramrao, Anna Tarren, Dhimant Desai, David F. Claxton, Sinisa Dovat, Arati Sharma

Blood (2021) 138 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2021-154542

Published: 2021

Journal Articles

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study

Yishai Ofran, Zhuoxin Sun, Jacob M. Rowe, David F. Claxton, Martin S. Tallman, Daniel A. Arber, Ari Melnick, Ross L. Levine, Elisabeth Paietta, John E. Godwin, Hillard M Lazarus, Selina M. Luger, James M. Foran, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 413.

https://doi.org/10.1182/blood-2021-149356

Published: 2021

Journal Articles

Hottip -Mediated R-Loops Regulate CTCF TAD Boundary to Control WNT/b-Catenin Pathway in AML Genome

Huacheng Luo, PhD, Ganqian Zhu, PhD, Xiaoyan Ma, MD PhD, David F. Claxton, MD, Yi Qiu, PhD, Mingjiang Xu, MDPhD, Suming Huang, PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137816

Published: 2020

Journal Articles

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia

Melat T. Gebru, Jennifer M. Atkinson, Megan M. Young, Lijun Zhang, Zhenyuan Tang, Zhenqiu Liu, Pinyi Lu, Christopher M. Dower, Longgui Chen, Charyguly Annageldiyev, Arati Sharma, Yuka Imamura Kawasawa, Zhongming Zhao, Barbara A. Miller, David F. Claxton, Hong-Gang Wang

Blood (2020) 136 (9): 1067–1079.

https://doi.org/10.1182/blood.2019003124

Published: 2020

Includes: Supplemental data

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

Christopher J Pizzola, MD MPH, Kevin L Rakszawski, MD, W. Christopher Ehmann, MD, Witold B. Rybka, MD, Baldeep Wirk, MD, Seema Naik, MD, Hong Zheng, MD PhD, Brook Silar, Gina Mackey, CCRP, Shin Mineishi, MD, Kentaro Minagawa, MD PhD, David F. Claxton, MD

Blood (2019) 134 (Supplement_1): 5724.

https://doi.org/10.1182/blood-2019-128817

Published: 2019

Journal Articles

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F. List, MD, Zhuoxin Sun, PhD, Amit Verma, MBBS, John M. Bennett, MD, Kathy McGraw, PhD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD, Timothy R. Wassenaar, MD, Selina M. Luger, MD FRCPC, Ryan J. Mattison, MD, Puneet S. Cheema, MD, Jessica K. Altman, David F. Claxton, MD, Charles A. Schiffer, MD, Andrew S. Artz, MD, Mark Litzow, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 842.

https://doi.org/10.1182/blood-2019-127274

Published: 2019

Journal Articles

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Blood (2019) 133 (14): 1548–1559.

https://doi.org/10.1182/blood-2018-10-881961

Published: 2019

Includes: Supplemental data

Journal Articles

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

James M. Foran, MD, Zhuoxin Sun, PhD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, David F. Claxton, MD, Hillard M Lazarus, MD, Daniel A. Arber, MD, Jacob M. Rowe, MD, John Godwin, MD, Yanming Zhang, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Keith W. Pratz, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2018-99-117838

Published: 2018

Journal Articles

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

Bei Jia, MD PhD, Chenchen Zhao, MD, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 5250.

https://doi.org/10.1182/blood-2018-99-113578

Published: 2018

Journal Articles

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Jeffrey J Pu, MD PhD, Matthew Nemesure, W. Christopher Ehmann, MD, David F Claxton, MD, Joseph J Drabick, MD, Anna C Salzberg, Yuka I Kawasawa, PhD, Elliot Epner, MD PhD

Blood (2018) 132 (Supplement 1): 5295.

https://doi.org/10.1182/blood-2018-99-118192

Published: 2018

NARROW

HoxBlinc LncRNA Reprograms CTCF Independent TADs to Drive Leukemic Transcription and HSC Dysregulation in NUP98 Fusion Transformed Leukemia

Risk Factors for CMV Infection, Including HLA Disparity and Ptcy Transplant in the Era of Letermovir Prophylaxis

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial

The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma

Real World Outcomes of Chronic Myeloid Leukemia in Era of Tyrosine Kinase Inhibitors a Single Center Experience

Viridans Group Streptococcal Bacteremia after Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide

Engraftment Kinetics and Recipient Chimerism Increase to Predict Leukemia Relapse By Ptcy and Non-Ptcy Transplant

Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

DJ4 Targets Rho-associated Protein Kinase Pathway and Attenuates Disease Progression in Pre-clinical Murine Models of Acute Myeloid Leukemia

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study

Hottip -Mediated R-Loops Regulate CTCF TAD Boundary to Control WNT/b-Catenin Pathway in AML Genome

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only